Ocumension Therapeutics (HKG:1477)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
7.33
+0.37 (5.32%)
At close: Mar 27, 2026
Market Cap5.98B +57.1%
Revenue (ttm)895.09M +92.7%
Net Income-176.74M
EPS-0.22
Shares Out815.38M
PE Ration/a
Forward PE92.41
Dividendn/a
Ex-Dividend Daten/a
Volume1,455,893
Average Volume913,675
Open7.00
Previous Close6.96
Day's Range6.96 - 7.40
52-Week Range3.91 - 12.23
Beta0.52
RSI56.85
Earnings DateMar 26, 2026

About Ocumension Therapeutics

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, age-related mac... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 505
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1477
Full Company Profile

Financial Performance

In 2025, Ocumension Therapeutics's revenue was 804.35 million, an increase of 92.75% compared to the previous year's 417.31 million. Losses were -158.82 million, -40.80% less than in 2024.

Financial numbers in CNY Financial Statements